Under the sudden change in the painting style of the A-share market in the new year, various institutions have increased their research efforts. In the first four trading days of the week, the agency investigated 155 companies. Among them, Huadong Medicine Co.Ltd(000963) is the most concerned by institutions. In terms of industry, among the companies surveyed by more than 10 institutions, pharmaceutical stocks are the most concerned.
in 2022, the research of "open door green" institutions was busy
In the extreme structural market in 2021, the stock index, which rose later, also rose by 4.8%, and closed at three consecutive positive annual lines for the first time since 1994, making many investors full of expectations for the market in the new year. However, in the first week of 2022, A-shares turned down sharply; In just four trading days, the three major indexes suffered four consecutive falls, the Shanghai index fell 3600 points, and the gem index fell nearly 7%. The unexpected arrival of the "open door green" market undoubtedly cast a shadow on the hearts of investors.
The beginning of the new year was unfavorable. The track stocks that rose sharply in the early stage fell sharply, while the undervalued blue chips that fell endlessly strengthened. With the sudden change of market painting style, various institutions have increased their research efforts. According to statistics, in the first week of 2022, the institution surveyed 155 listed companies. According to the calculation of only 4 working days in that week, the institution surveyed more than 38 companies on an average daily basis. It is worth mentioning that 63 companies have been investigated by more than 10 organizations.
Among them, the most concerned is Huadong Medicine Co.Ltd(000963) (000963). It is disclosed that on January 5, the company received 288 institutions including 74 public funds, 37 securities companies, 47 private placement, 13 insurance funds and 16 overseas institutions. The research mainly focuses on the expansion of Huadong Medicine Co.Ltd(000963) in the field of industrial microbiology. It is reported that Huadong Medicine Co.Ltd(000963) has been deeply cultivated in the field of industrial microbiology for many years. The company's core products are bailing capsule, acarbose, cyclosporine, mycophenolate mofetil and tacrolimus.
Huadong Medicine Co.Ltd(000963) said in the survey that the company's strategic concept of industrial microbial development is to extend vertically from the industrial end to the upstream, and horizontally from medicine to great health, special functional chemicals and materials. Based on the three elements of innovative technology, industrial layout and international development, the company focuses on pharmaceutical raw materials and high-end intermediates, special functional chemicals, great health and medical and American raw materials Biomaterials, enzyme preparations and microbial innovative drugs.
Huachang high tech, acquired by the company at the end of last year, is the focus of the organization. Huadong Medicine Co.Ltd(000963) said that the nucleosides planned to be produced by Huachang high tech mainly involve modified nucleosides, which can be used in the field of mRNA; Protective nucleosides can be used in the field of oligonucleotide drugs; Triphosphorylated nucleosides may directly enter the terminal application in drugs. In terms of capacity investment, Huachang high tech's capacity climbing will have an overall scheme design, which will be made public after obtaining the approval of relevant local departments.
In addition, Tibet Mineral Development Co.Ltd(000762) (000762), Ganyuan Foods Co.Ltd(002991) (002991), Northking Information Technology Co.Ltd(002987) (002987) also received a cluster survey from 224, 120 and 116 institutions respectively. Zhejiang Dun'An Artificial Environment Co.Ltd(002011) (002011), Chongqing Sokon Industry Group Stock Co.Ltd(601127) (601127), Jl Mag Rare-Earth Co.Ltd(300748) (300748), Anhui Xinbo Aluminum Co.Ltd(003038) (003038), Zhejiang Xianju Pharmaceutical Co.Ltd(002332) (002332), Guangdong Chj Industry Co.Ltd(002345) (002345), Guangzhou Goaland Energy Conservation Tech Co.Ltd(300499) (300499) have also been investigated by more than 50 institutions.
In terms of the number of institutional research, Tibet Mineral Development Co.Ltd(000762) (000762) is the most intensive, and it has received 5 institutional research. Guangdong Chj Industry Co.Ltd(002345) (002345), Zhejiang Weixing Industrial Development Co.Ltd(002003) (002003) ranked second in three institutional surveys, while companies such as Northking Information Technology Co.Ltd(002987) (002987), Guangzhou Goaland Energy Conservation Tech Co.Ltd(300499) , Skyworth data (00810) Zhejiang Daily Digital Culture Group Co.Ltd(600633) (600633), Zhejiang Rongsheng Environmental Protection Paper Joint Stock Co.Ltd(603165) (603165), Gansu Jingyuan Coal Industry And Electricity Power Co.Ltd(000552) (000552), Tangrenshen Group Co.Ltd(002567) (002567), Anhui Truchum Advanced Materials And Technology Co.Ltd(002171) (002171), Livzon Pharmaceutical Group Inc(000513) (000513), Moon Environment Technology Co.Ltd(000811) (000811), Huaming Power Equipment Co.Ltd(002270) (002270), Sai Microelectronics Inc(300456) (300456) accepted two institutional surveys.
the pharmaceutical and mechanical equipment industries are the most concerned
In terms of the types of research institutions, securities companies have the highest participation. According to the data disclosed by listed companies, among the 155 companies surveyed by institutions, 130 appeared securities companies, that is, 83.87% of the research activities of listed companies were participated by securities companies; Among the 110 company researchers, fund companies ranked second, and participated in 70.97% of the research activities; Sunshine private placement surveyed 68 companies, ranking third; Venture capital and overseas institutions, which are good at steady investment, visited 56 and 34 listed companies respectively.
Industry insiders believe that the concerns behind different research institutions are different. As a seller's organization, securities companies pay attention to mining information from research and processing "sharing" to the market; Public and private institutions pay more attention to investment opportunities and direct trading opportunities brought by research; Insurance and insurance asset management currently focus on finding the object of portfolio allocation through research; The research track of overseas institutions represents the layout idea of long-term and stable funds in the market. Investors should pay more attention to institutional research stocks. First, institutional research behavior will not be aimless. Second, institutions usually choose the layout after finding investment highlights in the research.
In terms of industry, the 63 listed companies surveyed by more than 10 group organizations in the first week of 2022 are mainly concentrated in the industries of medicine and Biology (10), mechanical equipment (8), non-ferrous metals (5), computers (4), food and beverage (4), power equipment (4), agriculture, forestry, animal husbandry and fishery (3), building materials (3), basic chemical industry (3), electronics (3), etc, There are 2 or less companies surveyed in other industries. From this point of view, pharmaceutical stocks received the most institutional attention in the first week of the new year.
In 2021, the overall performance of the pharmaceutical sector was poor. In the first trading week of 2022, the pharmaceutical sector continued to fluctuate, while the traditional Chinese medicine sector rose sharply. In this context, the pharmaceutical market has attracted much attention. Industry insiders pointed out that the growth rate of industry fundamentals in 2021 is high before and low after. Under the influence of the base, the growth rate of the industry in 2022 may be low before and high after. The whole year is expected to be reflected in the trend of quarterly acceleration, which will support the trend of the pharmaceutical sector in 2022. Considering the good growth of the industry performance in 2021, but the decline of the pharmaceutical sector, the valuation level of many companies has been better digested.
In the view of market participants, the previous "drinking" and "taking medicine" market supported "half" of a shares. However, in 2021, the world entered the post epidemic era, and the logic began to change. On the one hand, it led to potential performance risks; On the other hand, the performance outbreak during the epidemic is not necessarily sustainable, and the growth rate of enterprise performance will slow down; In addition, the valuation of some companies in the sector has been relatively high, and the pharmaceutical sector has entered the adjustment stage. However, from the perspective of investment, the decline of valuation is a good time to "copy the bottom", but it is crucial to "copy" what stocks.
companies surveyed by more than 10 institutions in the first week of 2022
(source: Investment express)
